Ozmosi | BBT-001 Drug Profile
Contact Us
Drug Profile
Using advanced filters...
Advanced Search [+]

BBT-001

Alternative Names: BBT-001, BBT 001, BBT001
Clinical Status: Active
Latest Update: 2026-04-01
Latest Update Note: News Article

Product Description

Mechanisms of Action: IL31 Inhibitor, IL4 Inhibitor

Novel Mechanism: No

Modality: Bispecific Antibody

Route of Administration: Injection

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Bambusa Therapeutics
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BBT-001

Countries in Clinic: Australia, China, New Zealand, United States

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

  • Clinical Outcomes Expected - Bambusa Therapeutics, Inc. announced they will present P1 Dermatitis, Atopic results in 3Q26 for BBT-001
  • Clinical Outcomes Reported - Bambusa Therapeutics presented P1 Dermatitis, Atopic results on 2026-04-01 for BBT-001

Highest Development Phases

Phase 1: Dermatitis, Atopic

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT06808477

 BBT001-001

P1

Recruiting

Dermatitis, Atopic

2026-08-21

2025-11-13

Patient Enrollment|Primary Endpoints

NCT07239947

 BBT001-002

P1

Recruiting

Dermatitis, Atopic

2026-08-31

2025-11-21

Primary Endpoints|Treatments

Recent News Events

Date

Type

Title

04/01/2026

News Article

 Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

03/19/2026

News Article

 Bambusa Therapeutics Appoints Todd James Chief Financial Officer

01/06/2026

News Article

 Bambusa Therapeutics Announces First Patient Dosed in Phase Ib Proof-of-Concept COPD Study of BBT002, Reinforcing Bispecific Pipeline Momentum

09/25/2025

News Article

 Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions